Reading PRGO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRGO free→Reading PRGO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRGO free→NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality cannot be assessed as the company was unprofitable over the past year. Peer multiples imply a price about 54% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. If PRGO cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $10.68. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $11 PRGO trades at 6× p/e, below its 13× p/e peer median. Our $23 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 54% below a flat-multiple fair value, below our forecast of about -2%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted -0.10x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.36 → $0.36 (+0.0% / 30d). 0 raised, 3 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 40% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$215.
How much price usually moves either way.
On a bad day, this stock has moved -$426.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,556.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if Perrigo can meet its full-year guidance after a challenging Q1.
Confirms one read:Q2 earnings report shows adjusted EPS within the guided range of $2.00 to $2.30.
Confirms the other:Q2 earnings report shows adjusted EPS below the guided range.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PRGO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
President and Chief Executive Officer — Patrick Lockwood-Taylor: Resigned due to personal conduct inconsistent with the Company's Code of Conduct and core values.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PRGO Perrigo | Above typical Show detailsSector percentile: 78 of 100 | inexpensive | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 63 of 100 | full | low |
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on market share gains through the implementation of the Three-S plan.
Reaffirm full-year 2026 outlook with expectations for second-half improvement.
Use proceeds from divestitures, such as the Dermacosmetics business, to reduce debt.
Management aims to improve operating cash flow, which has been a recurring focus.
The company is committed to maintaining its dividend payments as part of its capital allocation strategy.
Why it matters: Gaining market share can signal effective execution of the Three-S plan and drive revenue growth.
Confirms:Reported market share gains in the Self Care segment of at least 100 basis points.
Disproves:Market share declines or stagnation in the Self Care segment.
Why it matters: Having a permanent CEO can stabilize leadership. This helps Perrigo's plans and builds investor trust.
Confirms:A permanent CEO has been announced. This person matches Perrigo's strategic goals.
Disproves:Interim leadership continues for over six months. There is still no permanent appointment.
Why it matters: Reducing debt can make finances more stable. This helps with future growth plans.
Confirms:They announced a debt cut of at least $300 million after selling Dermacosmetics.
Disproves:No major debt reduction is reported in the next financial update.
Why it matters: Earnings results will show how well the company is doing and its trends.
Confirms one read:Earnings beat expectations with revenue growth over 5%.
Confirms the other:Earnings miss expectations with revenue growth below 0%.
Why it matters: Improving cash flow shows Perrigo is managing costs better. This is key for growth.
Confirms:Operating cash flow improves year over year by more than 10%.
Disproves:Operating cash flow declines year over year or stays flat.
Why it matters: Maintaining the dividend shows commitment to shareholders. A cut could signal deeper issues.
Confirms:Perrigo maintains its dividend at $0.29 per share in Q2.
Disproves:Perrigo cuts the dividend below $0.29 per share.
Why it matters: Completing the acquisition may help Perrigo grow. It could also improve its market position.
Confirms:The acquisition closes on schedule and is confirmed in a press release.
Disproves:The acquisition is postponed or called off.
Results of Operations and Financial Condition On May 6, 2026, Perrigo Company plc (the “Company”) released earnings for the first quarter ended March 28, 2026. The press release related to the Company’s earnings is attached as Exhibit 99.1. The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where a…
Completion of Acquisition of Disposition of Assets. As previously disclosed, on July 13, 2025, Perrigo Company plc (the “Company”) entered into a Master Sale and Purchase Agreement (the “Agreement”) with Kairos Bidco AB (“Kairos”), an affiliate of Karo Healthcare AB (“Karo”) and an investment vehicle managed by an affiliate of KKR & Co., Inc. (“KKR”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell and Karo agreed to acquire (1) all of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2026, Perrigo Company plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the results of which are set forth in
and 7.01 of Form 8-K. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Registrant) PERRIGO COMPANY PLC By: /s/ Eduardo Bezerra Dated: April 22, 2026 Eduardo Bezerra Chief Financial Officer